In the AIDS pandemic, access to experimental treatments has become an important element of community-standard medical care. Rates of AIDS and HIV infection are significantly higher in prison and jail populations than in the U.S. population at large; however, prisoners are denied access to AIDS-related clinical trials in all but a handful of jurisdictions. The author argues for expanded prisoner access to AIDS-related clinical trials and demonstrates that such access is ethical and feasible. Enrolling prisoners in AIDS-related trials would stand to benefit not only affected prisoners but also clinical researchers seeking to gather information on the efficacy of treatments in all population groups contained within the larger HIV-infected population, including African Americans, Latinos, and IV drug users. Existing federal regulations, properly enforced, provide prisoners with adequate protection from exploitation conducted in the name of science. Barriers remain, in the form of state laws, correctional policies, and practical obstacles presented by the prison environment. However, as the author describes, research institutions in several states have succeeded in incorporating prisoners into clinical drug trials.
Get full access to this article
View all access options for this article.
References
1.
American Correctional Association. (1990). Standards for adult correctional institutions (3rd ed., Standard No. 3-4373). Laurel, MD: Author.
2.
Beck, A., Gilliard, D., Greenfeld, L., Harlow, C., Hester, T., Jankowski, L., Snell, T., Stephan, J., & Morton, D. (1993, March). Survey of state prison inmates 1991 (NCJ-136949). Washington, DC: U.S. Department of Justice, Bureau of Justice Statistics.
3.
Bosarge, B. B. (1993, November 17). Massachusetts lifts ban on prisoners testing drugs. Corrections Digest, p. 3.
4.
Centers for Disease Control and Prevention. (1994). HIV/AIDS surveillance report (Vol. 6, No. 1). Atlanta, GA: Author.
5.
Committee on Government Operations. (1991, December 2). Obstacles to drug development for HIV-related opportunistic infections (7th Report). (Report submitted to the 102d Congress)
6.
D'Eramo, J. E., Kirschenbaum, D. Z., McCarthy, M., Davis, T., & AIDS Treatment Resources. (1991). Women and minorities have less access to AIDS drug trials. (From the International Conference on AIDS, Florence, Italy. Abstract reproduced in conference program. Abstract No. W.D. 4291, Vol. 7, No. 2)
7.
Dubler, N. N., & Sidel, V. W. (1989). On research on HIV infection and AIDS in correctional institutions. The Milbank Quarterly, 67, 171-208.
8.
Duke, K., (1993, Fall). Achieving balance: Biomedical research and inmates. Corhealth, p. 2.
9.
Easterbrook, P. J., Keruly, J. C., Creagh-Kirk, T., Richman, D. D., Chaisson, R. E., Moore, R. D., & the Zidovudine Epidemiology Study Group. (1991). Racial and ethnic differences in outcome in ZDV-treated patients with advanced HIV disease. Journal of the American Medical Association, 266, 2713-2718.
10.
El-Sadr, W., & Capps, L. (1992). The challenge of minority recruitment in clinical trials for AIDS. Journal of the American Medical Association, 267, 954-957.
11.
Gilliard, D. K., & Beck, A. J. (1994, June). Prisoners in 1993. Bureau of Justice Statistics Bulletin (NCJ-147036). Washington, DC: U.S. Department of Justice, Bureau of Justice Statistics.
12.
Hamilton, J. D., Hartigan, P. M., Simberkoff, M. S., & the V.A. Cooperative Study Group. (1991). Early versus later zidovudine treatment of symptomatic HIV infection: Results of a VA cooperative study. Clinical Research, 39. (Abstract No. 216A)
13.
Hammett, T. M., Harrold, L., Gross, M., & Epstein, J. (1994, January). 1992 update: HIV/AIDS in correctional facilities. Washington, DC: U.S. Department of Justice, Office of Justice Programs, National Institute of Justice.
14.
Harlow, C. W. (1993, September). HIV in U.S. prisons and jails (Bureau of Justice Statistics Special Report No. NCJ-143292). Washington, DC: Bureau of Justice Statistics.
15.
Holmes, S. A. (1994, October 28). Ranks of inmates reach one million in a 2-decade rise. New York Times, p. 1.
16.
Is there still too much extrapolation from data on middle-aged White men? (1990). Journal of the American Medical Association, 263, 1049-1050.
17.
Kolata, G. (1994, January 22). When the dying enroll in studies: A debate over false hopes. New York Times, p. A7.
18.
Kunz, A. Y. (1993). Challenges in AIDS clinical trials. Applied Clinical Trials, 2, 62-68.
19.
Lagakos, S., Fischl, M., Stein, D., Lim., L., & Volberdine, P. (1991). Effects of ZDV therapy in minority and other subpopulations with early HIV infection. Journal of the American Medical Association, 266, 2709-2712.
20.
Lee, F. R. (1994, November 8). U.S. cuts AIDS research grants in New York City. New York Times, pp. A1, B7.
21.
Levine, C., Dubler, N. N., & Levine, R. J. (1991, January-April). Building a new consensus: Ethical principles and policies for clinical research on HIV/AIDS. Institutional Review Board, p. 13.
22.
Merkatz, R. B., Temple, R., Sobel, S., Feiden, K., Kessler, D., & the Working Group on Women in Clinical Trials. (1993). Women in clinical trials of new drugs: A change in Food and Drug Administration policy. New England Journal of Medicine, 329, 292-296.
23.
Moore, R. D., Hidalgo, J., Sugland, B. W., & Chaisson, R. (1991). ZDV and the natural history of the acquired immune deficiency syndrome. New England Journal of Medicine, 324, 1412-1416.
24.
Novick, A. (1989). Commentary: Clinical trials with vulnerable or disrespected subjects. AIDS & Public Policy, 4, 125-130.
25.
Potler, C., Sharp, V. L., & Remick, S. (1994). Prisoners' access to HIV experimental trials: Legal, ethical, and practical considerations. Journal of Acquired Immune Deficiency Syndromes, 7, 1086-1094.
26.
Rothman, D. J. (1994, January 9). Government guinea pigs. New York Times.
27.
Schneider, K. (1993, December 17). Secret nuclear research on people comes to light. New York Times, p. A1.
28.
Schneider, K. (1994a, January 14). A spreading light on radiation tests. New York Times.
29.
Schneider, K. (1994b, January 14). Two recall radiation tests on them. New York Times.
30.
Schneider, K. (1994c, March 2). Scientists share in pain of experiment debates. New York Times, p. A12.
31.
Surgeon General's report to the American public on HIV infection and AIDS (No. 534-369). (1993). Washington, DC: U.S. Government Printing Office.
32.
Svensson, C. K. (1989). Representations of American Blacks in clinical trials of new drugs. Journal of the American Medical Association, 261, 263-265.
33.
Weiner, J., & Anno, B. J. (1992). The crisis in health care: The impact of the national drug control strategy on correctional health services. Annals of Internal Medicine, 117, 71-77.
34.
Wermerling, D. P., & Swelwitz, A. S. (1993). Current issues surrounding women and minorities in drug trials. Annals of Pharmacotherapy, 27, 904-910.
35.
WHO Global Programme on AIDS. (1993, March). WHO guidelines on HIV infection and AIDS in prisons. Geneva: United Nations.
